Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).

Timeline

Start

2021-07-08

Primary completion

2024-07-25

Completion

2024-08-07

Outcome

Met primary endpoint

release “randomized withdrawal trial, which on the primary endpoint found time to relapse during the 26-week double-blind treatment phase was significantly longer” jnj.com ↗

Drugs

Indications